


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-37 (canceled)

38. (new) A compound of the formula (I):



wherein

bonds represented by the dashed lines are present or absent;

R₁ is -(CH₂)₂₋₄-NH-SO₂-R₄;

R₂ is hydrogen, -C₁₋₄ alkyl, or -C₁₋₄ alkyl-O-C₁₋₄ alkyl;

R₄ is C₁₋₄ alkyl;

n is 0 and each R present is independently selected from the group consisting of C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, halogen, and trifluoromethyl; or a pharmaceutically acceptable salt thereof.

39. (new) A compound or salt according to claim 38, wherein R₁ is -(CH₂)₄-NH-SO₂-C₁₋₄ alkyl, and bonds represented by the dashed lines are present.

40. (new) A compound or salt according to claim 39, wherein R₁ is -(CH₂)₄-NH-SO₂-CH₃, and R₂ is -C₁₋₄ alkyl.

41. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 38 and a pharmaceutically acceptable carrier.

42. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 39 and a pharmaceutically acceptable carrier.

43. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 40 and a pharmaceutically acceptable carrier.

44. (new) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound of claim 38 to the animal.

45. (new) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound of claim 39 to the animal.

46. (new) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound of claim 40 to the animal.